Non-Hodgkin Lymphoma
T-DM1 Shows Tolerability in HER2+ Biliary Tract Adenocarcinoma
T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
Palliative Care Consultations Enhance QOL, Reduce Costs in End-of-Life Esophageal Cancer Care
Palliative care consultations in esophageal cancer improved QOL and reduced financial burden, according to ASCO GI poster findings.
LaPelusa’s Journey in the Dynamic Field of GI Oncology
In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Real-World Data Shows NALRIFOX Boosts OS vs FOLFIRINOX in PDAC
NALRIFOX showed numerically better overall survival vs FOLFIRINOX as frontline treatment in PDAC, per real-world analysis results.
ASCEND Trial of Certepetide Plus Chemo Fails to Improve PFS in Metastatic PDAC
Certepetide plus chemotherapy showed signs of efficacy but failed to improve progression-free survival in metastatic PDAC in the ASCEND trial.
